| P2093 | author name string | Mark Kemp | |
| P2860 | cites work | Enzymatic characterisation of USP7 deubiquitinating activity and inhibition | Q39563641 |
| | Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. | Q39636568 |
| | Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. | Q39730830 |
| | Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases? | Q39812916 |
| | Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells | Q39813804 |
| | Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors | Q40142929 |
| | A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents | Q41515742 |
| | Ubiquitin-specific protease 4 is inhibited by its ubiquitin-like domain | Q41861997 |
| | The DUSP-Ubl domain of USP4 enhances its catalytic efficiency by promoting ubiquitin exchange | Q42028148 |
| | Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes | Q43148533 |
| | Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening | Q43834622 |
| | Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. | Q44594725 |
| | Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition | Q44934471 |
| | Harnessing the oxidation susceptibility of deubiquitinases for inhibition with small molecules | Q46823938 |
| | Small-Molecule Inhibitors and Probes for Ubiquitin- and Ubiquitin-Like-Specific Proteases | Q58214454 |
| | The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis | Q70732451 |
| | Kinetic studies of isopeptidase T: modulation of peptidase activity by ubiquitin | Q71715465 |
| | Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes | Q74252080 |
| | High incidence of ubiquitin-like domains in human ubiquitin-specific proteases | Q80539443 |
| | Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists | Q81620167 |
| | Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization | Q24292930 |
| | The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy | Q24298748 |
| | USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria | Q24316174 |
| | UAF1 is a subunit of multiple deubiquitinating enzyme complexes | Q24329003 |
| | Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13 | Q24338972 |
| | Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14 | Q24537053 |
| | Deubiquitinating enzymes in cellular signaling and disease regulation | Q26801232 |
| | Advances in the development of SUMO specific protease (SENP) inhibitors | Q26864235 |
| | Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde | Q27640257 |
| | Dipeptidyl nitrile inhibitors of Cathepsin L | Q27655858 |
| | Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors | Q27659746 |
| | Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation | Q27661287 |
| | Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein−Ligand X-ray Structure and Biological Evaluation | Q27662127 |
| | Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains | Q27671821 |
| | Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase | Q27674789 |
| | The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK) | Q27679250 |
| | X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases | Q27681891 |
| | Structure and Catalytic Regulatory Function of Ubiquitin Specific Protease 11 N-Terminal and Ubiquitin-like Domains | Q27683231 |
| | Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features | Q27694423 |
| | Catching a DUB in the act: novel ubiquitin-based active site directed probes | Q38280690 |
| | Monitoring Target Engagement of Deubiquitylating Enzymes Using Activity Probes: Past, Present, and Future | Q38822748 |
| | Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies | Q38894421 |
| | USP30 deubiquitylates mitochondrial Parkin substrates and restricts apoptotic cell death | Q38903534 |
| | The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. | Q39006249 |
| | Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth | Q39023236 |
| | Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival | Q39148897 |
| | Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes | Q39437160 |
| | Inhibition of proteasome deubiquitinating activity as a new cancer therapy | Q39447379 |
| | The USP1/UAF1 complex promotes double-strand break repair through homologous recombination | Q39560571 |
| | The ubiquitin system | Q27860803 |
| | Breaking the chains: structure and function of the deubiquitinases | Q28131738 |
| | A dynamic role of HAUSP in the p53-Mdm2 pathway | Q28253645 |
| | The ubiquitin code | Q28265104 |
| | The role of UBL domains in ubiquitin-specific proteases | Q28267230 |
| | Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8) | Q28268036 |
| | The JAMM motif of human deubiquitinase Poh1 is essential for cell viability | Q28284132 |
| | A genomic and functional inventory of deubiquitinating enzymes | Q28284911 |
| | Polyubiquitin chains: polymeric protein signals | Q28294396 |
| | A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance | Q28395203 |
| | Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response | Q28481001 |
| | A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30 | Q28504988 |
| | Crystal Structure of USP7 Ubiquitin-like Domains with an ICP0 Peptide Reveals a Novel Mechanism Used by Viral and Cellular Proteins to Target USP7 | Q28547943 |
| | Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15 | Q28834132 |
| | Deubiquitinases (DUBs) and DUB inhibitors: a patent review | Q28834608 |
| | New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 |
| | Enhancement of proteasome activity by a small-molecule inhibitor of USP14 | Q29616735 |
| | Targeting deubiquitinases enabled by chemical synthesis of proteins. | Q31046568 |
| | Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening | Q33296122 |
| | A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication | Q33375590 |
| | Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease | Q33488957 |
| | Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments | Q33523595 |
| | Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. | Q33873915 |
| | A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination | Q33998170 |
| | A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes | Q34056133 |
| | An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes | Q34063163 |
| | A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. | Q34089593 |
| | Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling | Q34152661 |
| | Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme | Q34240760 |
| | Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line | Q34266771 |
| | Identification Of Small Molecule TRABID Deubiquitinase Inhibitors By Computation-Based Virtual Screen. | Q34268517 |
| | Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer | Q34313778 |
| | Families of cysteine peptidases. | Q34317817 |
| | Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor | Q34345359 |
| | Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus | Q34455805 |
| | Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1 | Q34502063 |
| | Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression | Q34683256 |
| | Macromolecular juggling by ubiquitylation enzymes | Q34782977 |
| | Development of inhibitors in the ubiquitination cascade | Q35044801 |
| | A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases | Q35175346 |
| | Screening of DUB activity and specificity by MALDI-TOF mass spectrometry | Q35232335 |
| | Inhibiting the deubiquitinating enzymes (DUBs). | Q35386992 |
| | Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases | Q35559055 |
| | Prolonged and tunable residence time using reversible covalent kinase inhibitors | Q35756228 |
| | Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting | Q35864085 |
| | Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells | Q35934305 |
| | Ubiquitin C-terminal hydrolase l1 in tumorigenesis | Q36091119 |
| | Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications | Q36095703 |
| | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q36338365 |
| | Emerging trends in metalloprotein inhibition | Q36956841 |
| | Protein partners of deubiquitinating enzymes | Q37237774 |
| | Strategies for the identification of novel inhibitors of deubiquitinating enzymes | Q37269483 |
| | Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? | Q37428071 |
| | USP8 is a novel target for overcoming gefitinib resistance in lung cancer | Q37476722 |
| | DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors | Q37485753 |
| | USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis | Q37577477 |
| | Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures | Q37579637 |
| | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer | Q37660030 |
| | Emerging roles of deubiquitinases in cancer-associated pathways | Q37674364 |
| | Peptidomimetic inhibitors of cathepsin K. | Q37718837 |
| | Deubiquitinases in cancer: new functions and therapeutic options. | Q37945451 |
| | Proteasome inhibitors: an expanding army attacking a unique target | Q37979388 |
| | Deubiquitylating enzymes and DNA damage response pathways | Q38109871 |
| | Deubiquitylases from genes to organism | Q38125278 |
| | Regulation of deubiquitinase proteolytic activity | Q38130360 |
| | Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics | Q38203366 |
| | Molecular pathways: translational potential of deubiquitinases as drug targets | Q38236205 |
| | Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. | Q38244793 |
| P304 | page(s) | 149-192 | |
| P577 | publication date | 2016-01-12 | |
| P1433 | published in | Progress in medicinal chemistry | Q27712806 |
| P1476 | title | Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors | |
| P478 | volume | 55 | |